Leabaneng Tawe

Leabaneng Tawe

Auto-generated profile, based on publicly available information

Leabaneng Tawe

Botswana‐University of Pennsylvania Partnership Gaborone Botswana

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
SPSweta M. Patel
Sweta M. Patel
JFJohn Farirai
John Farirai
MPMohamed Z. Patel
Mohamed Z. Patel
SBSefelani Boiditswe
Sefelani Boiditswe
LTLeabaneng Tawe
Leabaneng Tawe
MKMatthew S. Kelly
Matthew S. Kelly
Children living with HIV (CLWH) are at high risk of colonization and infection by bacterial respiratory pathogens, though this risk can be reduced by other microbes in the upper respiratory microbiome. The impact of HIV infection on development of the upper respiratory microbiome during childhood is poorly understood, and we sought to address this knowledge gap by identifying associations between HIV infection and the nasopharyngeal microbiomes of children in Botswana. We enrolled Batswana CLWH (<5 years) and age- and sex-matched HIV-exposed, uninfected (HEU) and HIV-unexposed, uninfected (HUU) children in a cross-sectional study. We used shotgun metagenomic sequencing to compare the nasopharyngeal microbiomes of children by HIV status. Among the 143 children in this study, HIV infection and HIV-associated immunosuppression were associated with alterations in nasopharyngeal microbiome composition, including lower abundances of Corynebacterium species associated with respiratory health. These findings suggest that the upper respiratory microbiome may contribute to the high risk of bacterial respiratory infections among CLWH.

9 March 2026 in Health Science Reports
Verified
Journal Article
Open access
LTLeabaneng Tawe
Leabaneng Tawe
Background and Aim: Cervical cancer is a major public health issue in Botswana, driven by high HIV prevalence and limited screening access. Molecular detection of high‐risk human papillomavirus (hrHPV) is crucial for prevention and early diagnosis. The aim of this narrative review is to synthesize studies evaluating seven HPV detection platforms used in Botswana, focusing on diagnostic performance, feasibility, and scalability. Methods: A comprehensive literature search was conducted across PubMed, PMC, Google Scholar, and regional repositories up to July 2025 to identify studies evaluating HPV detection platforms in Botswana. Eligible studies included those assessing molecular HPV assays or genotyping tools in Botswana populations, reporting diagnostic performance or feasibility data. Data extracted covered study population characteristics, sample types, detection platforms, hrHPV prevalence, and performance metrics. Findings were qualitatively synthesized to compare platforms by sample type and application, as heterogeneity precluded meta‐analysis. Results: The Cepheid Xpert HPV assay, with near‐point‐of‐care capability, self‐sampling suitability, and high sensitivity (96%) and specificity (90%), is well‐suited for national programs despite costs of $15–$25 per test. AmpFire, costing $10–$15 per test, requires minimal equipment, offers good field feasibility (92% sensitivity, 88% specificity), and is promising for community deployment. Laboratory‐based assays like Roche Linear Array and Abbott RealTime deliver broader genotyping and > 93% sensitivity but require centralized infrastructure. PathoChip microarray detects novel HPV types yet is cost‐prohibitive (> $150/test). Double‐nested PCR aids retrospective formalin‐fixed paraffin‐embedded (FFPE) analysis but lacks practicality. These platforms collectively enhance cervical cancer prevention strategies in Botswana. Conclusions: This review identifies feasible HPV detection platforms for Botswana's cervical cancer control. Cepheid Xpert and AmpFire assays offer accurate, affordable, and field‐ready options for early diagnosis and wider screening access. Integrating these molecular tools into existing HIV and reproductive health services could enhance prevention, early detection, and progress toward WHO cervical cancer elimination goals.

17 November 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SKSetho Ruth Taboka Kgakatsi
Setho Ruth Taboka Kgakatsi
SGSomolekae Katlego Galetlale
Somolekae Katlego Galetlale
LTLeabaneng Tawe
Leabaneng Tawe
IKIshmael Kasvosve
Ishmael Kasvosve
JSJeremy Seth Slone
Jeremy Seth Slone
GPGiacomo Maria Paganotti
Giacomo Maria Paganotti